Bausch Health Companies Inc. Defined Benefit Plan, Funded (Unfunded) Status of Plan
Bausch Health Companies Inc. (BHC) had Defined Benefit Plan, Funded (Unfunded) Status of Plan of -$5.70 million as of 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Funded (Unfunded) Status of Plan
us-gaap:DefinedBenefitPlanFundedStatusOfPlan · last filed 2013-02-28
- 2012-12-31: Defined Benefit Plan, Funded (Unfunded) Status of Plan -$5.70M.
- 2011-12-31: Defined Benefit Plan, Funded (Unfunded) Status of Plan -$6.40M.
| Period end | Defined Benefit Plan, Funded (Unfunded) Status of Plan |
|---|---|
| 2012-12-31 | -$5.70M 10-K · filed 2013-02-28 |
| 2011-12-31 | -$6.40M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |